Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Facon

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Leukemia|November 11, 2006
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsS Jagannath, P G Richardson, P Sonneveld, et al.
Leukemia|May 26, 2012
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimensS Manier, M Barthelemy, G Fouquet, et al.
The American Journal of Medicine|July 1, 1996
Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosisE Hachulla, L Maulin, M Deveaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myelomaP Moreau, D Fiere, W R Bezwoda, et al.
Cancer Research|December 29, 1998
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignanciesH Avet-Loiseau, J Y Li, T Facon, et al.
La Revue De Medecine Interne|January 19, 2015
[Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation]G Fouquet, K Amouzou, L Renaud, et al.
British Journal of Haematology|December 1, 1996
Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS)C Mathiot, J Y Mary, E Tartour, et al.
The New England Journal of Medicine|July 11, 1996
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du MyélomeM Attal, J L Harousseau, A M Stoppa, et al.
Genes, Chromosomes & Cancer|January 19, 1999
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridizationH Avet-Loiseau, C Brigaudeau, N Morineau, et al.
Blood Cancer Journal|January 9, 2016
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trialN Raje, S Vadhan-Raj, W Willenbacher, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Leukemia|November 11, 2006
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsS Jagannath, P G Richardson, P Sonneveld, et al.
Leukemia|May 26, 2012
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimensS Manier, M Barthelemy, G Fouquet, et al.
The American Journal of Medicine|July 1, 1996
Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosisE Hachulla, L Maulin, M Deveaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myelomaP Moreau, D Fiere, W R Bezwoda, et al.
Cancer Research|December 29, 1998
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignanciesH Avet-Loiseau, J Y Li, T Facon, et al.
La Revue De Medecine Interne|January 19, 2015
[Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation]G Fouquet, K Amouzou, L Renaud, et al.
British Journal of Haematology|December 1, 1996
Soluble CD16 (sCD16), a marker of malignancy in individuals with monoclonal gammopathy of undetermined significance (MGUS)C Mathiot, J Y Mary, E Tartour, et al.
The New England Journal of Medicine|July 11, 1996
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du MyélomeM Attal, J L Harousseau, A M Stoppa, et al.
Genes, Chromosomes & Cancer|January 19, 1999
High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridizationH Avet-Loiseau, C Brigaudeau, N Morineau, et al.
Blood Cancer Journal|January 9, 2016
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trialN Raje, S Vadhan-Raj, W Willenbacher, et al.
Pageof 13